```html

Zollinger‑Ellison Syndrome – Ectopic Gastrin Production

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing neuroendocrine tumors (gastrinomas) develop, most often in the duodenum or pancreas. These tumors secrete large amounts of gastrin, a hormone that stimulates the stomach lining to produce excess gastric acid. The resulting hyperacidity leads to recurrent peptic ulcers, abdominal pain, and a host of other gastrointestinal problems.

Although ZES can occur at any age, it most commonly presents in people aged 30–60 years. An estimated 0.1–3 cases per million population are diagnosed each year worldwide, making it one of the rarest endocrine malignancies. Approximately 25 % of patients have an inherited form (MEN‑1 syndrome), while the remaining cases are sporadic.

Understanding ZES is crucial because uncontrolled gastric acid can cause severe complications, but with modern diagnostic tools and therapies, most patients achieve good symptom control and long‑term survival.

Symptoms

Symptoms arise from chronic gastric hypersecretion and from the tumor itself. The classic triad—refractory peptic ulcer disease, gastric‑acid hypersecretion, and a gastrinoma—may not be present in every patient.

Gastro‑intestinal symptoms

• Recurrent or refractory duodenal ulcers (often multiple and beyond the duodenum).
• Abdominal pain – usually epigastric, worsening 1–3 hours after meals.
• Diarrhea – acidic chyme irritates the intestine; can be watery, steatorrhea‑type, or cause fecal incontinence.
• Nausea and vomiting – may be related to ulcer complications or acid irritation.
• Gastric outlet obstruction – severe ulceration can lead to pyloric stenosis.

Systemic symptoms

• Weight loss – due to malabsorption and chronic pain.
• Fatigue – from anemia (often iron‑deficiency) or chronic disease.
• Osteoporosis – chronic acid loss can impair calcium absorption.
• Electrolyte disturbances – hypokalemia and metabolic alkalosis from persistent vomiting.

Signs of tumor burden

• Palpable abdominal mass (rare).
• Metastatic disease symptoms (e.g., liver pain, jaundice) if the tumor has spread.

Causes and Risk Factors

ZES is caused by gastrinomas, which are neuroendocrine tumors (NETs) that arise from the enterochromaffin‑like (ECL) cells of the gastrointestinal tract.

Primary causes

• Sporadic gastrinomas – ~75 % of cases; no identifiable inherited mutation.
• Multiple Endocrine Neoplasia type 1 (MEN‑1) – an autosomal‑dominant syndrome caused by mutations in the MEN1 tumor suppressor gene. Up to 25 % of ZES patients have MEN‑1.

Risk factors

• Family history of MEN‑1 or Zollinger‑Ellison syndrome.
• Genetic mutations in MEN1 or CDC73 (rare).
• Age >30 years (peak incidence).
• Male sex shows a slight predominance (≈55 % male).

Diagnosis

Diagnosing ZES requires confirmation of both hypergastrinemia and gastric acid hypersecretion, and then localizing the gastrinoma.

Initial laboratory work‑up

• Fasting serum gastrin level – values > 1000 pg/mL are highly suggestive; values > 150 pg/mL with gastric pH < 2 are also diagnostic. (Reference: Mayo Clinic).
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin administration (≥ 120 pg/mL increase) is positive for gastrinoma.
• Basic metabolic panel – assess potassium, bicarbonate, calcium, and vitamin D.
• Complete blood count – evaluate for anemia.

Acid‑production assessment

• Gastric pH testing – pH < 2 on fasting bedside testing confirms hyperacidity.
• 24‑hour gastric acid output – > 15 mEq/h is diagnostic but rarely needed.

Imaging for tumor localization

• Endoscopic ultrasound (EUS) – high sensitivity for small duodenal lesions.
• Multiphasic contrast‑enhanced CT or MRI – assess pancreas, liver, and lymph nodes.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – most sensitive for detecting primary and metastatic NETs.
• Selective arterial secretin stimulation – used when imaging is equivocal.

Histopathology

If surgical resection is performed, the tumor is examined for:

• Cellular morphology (well‑differentiated neuroendocrine tumor).
• Ki‑67 proliferation index – guides grading (G1‑G3).
• Immunohistochemistry for gastrin, chromogranin A, synaptophysin.

Treatment Options

Treatment aims to (i) control gastric acid secretion, (ii) remove or reduce tumor burden, and (iii) monitor for recurrence.

Medical therapy – acid control

• Proton pump inhibitors (PPIs) – first‑line, high‑dose (e.g., omeprazole 60 mg daily or equivalent). They normalize gastric pH in > 90 % of patients (source: CDC).
• H2‑receptor antagonists – may be added for breakthrough symptoms, but are less effective than PPIs.
• Long‑term PPI therapy is generally safe, but periodic monitoring of magnesium, vitamin B12, and bone density is advised.

Surgical management

• Curative resection – enucleation or pancreaticoduodenectomy (Whipple) when the tumor is localized and resectable.
• Debulking surgery – for unresectable or metastatic disease; reduces tumor burden and gastrin output.
• Patients with MEN‑1 often require a staged approach because multiple micro‑tumors are common.

Targeted and systemic therapies

• Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin release and can control tumor growth.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for patients with high somatostatin‑receptor expression and progressive disease.
• Chemotherapy – reserved for high‑grade (G3) neuroendocrine carcinomas; regimens include etoposide + cisplatin.
• Targeted agents – everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) have shown benefit in pancreatic NETs, though data specific to ZES are limited.

Lifestyle and supportive measures

• Small, frequent meals; avoid foods that trigger ulcer symptoms (spicy, acidic, caffeine).
• Stay hydrated; replace electrolytes if vomiting or diarrhea is frequent.
• Calcium and vitamin D supplementation if bone density is low.
• Quit smoking and limit alcohol, both of which worsen ulcer disease.

Living with Zollinger‑Ellison Syndrome – Ectopic Gastrin Production

Daily medication adherence

• Take PPIs exactly as prescribed – usually once or twice daily on an empty stomach.
• Set phone or app reminders for medication and follow‑up appointments.

Nutrition tips

• Choose low‑fat, low‑acid foods; bland proteins (chicken, fish), cooked vegetables, and whole grains are well tolerated.
• Limit citrus fruits, tomato‑based sauces, chocolate, and coffee.
• Consider a dietitian familiar with NETs for individualized meal planning.

Monitoring and follow‑up

• Serum gastrin level every 6–12 months (or sooner if symptoms change).
• Annual imaging (CT/MRI or ^68Ga‑DOTATATE PET) to detect recurrence or metastasis.
• Bone density scan every 2–3 years if on long‑term PPIs or with risk factors for osteoporosis.

Psychosocial support

• Join NET support groups (e.g., NETpatient.org, Carcinoid Cancer Foundation).
• Seek counseling if anxiety or depression about chronic illness arises.

Prevention

Because most ZES cases are sporadic, primary prevention is limited. However, certain steps can reduce risk or aid early detection:

• Genetic counseling and testing for individuals with a family history of MEN‑1.
• Regular screening endoscopy for MEN‑1 carriers starting in their 20s (per NIH guidelines).
• Avoid chronic use of medications that raise gastrin (e.g., long‑term H2 blockers) without medical supervision.

Complications

If untreated, the relentless acid output and tumor growth can lead to serious health problems:

• Refractory peptic ulcer disease – perforation, bleeding, or penetration into adjacent organs.
• Gastrointestinal hemorrhage – can be life‑threatening.
• Gastric outlet obstruction – requires surgical bypass.
• Malabsorption and severe diarrhea – leading to dehydration, electrolyte imbalance, and weight loss.
• Metastatic disease – liver, lymph nodes, or bone metastases occur in 40–60 % of patients at diagnosis.
• Neuroendocrine carcinoma transformation – high‑grade tumors have a poorer prognosis.
• Osteoporosis/fractures – from chronic acid loss of calcium and long‑term PPI use.

When to Seek Emergency Care

References

1. Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org/diseases-conditions/zollinger-ellison-syndrome/diagnosis-treatment/drc-20332784 (accessed May 2026).
2. National Cancer Institute. Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version. https://www.cancer.gov/types/neuroendocrine/hp/neuroendocrine-treatment-pdq (accessed May 2026).
3. World Health Organization. Classification of Tumours of the Digestive System. 5th ed. 2019.
4. Cleveland Clinic. Gastrinoma (Zollinger‑Ellison Syndrome). https://my.clevelandclinic.org/health/diseases/16417-zollinger-ellison-syndrome (accessed May 2026).
5. U.S. Centers for Disease Control and Prevention. Neuroendocrine Tumors. https://www.cdc.gov/cancer/neuroendocrine (accessed May 2026).
6. Famula, T.R., et al. “Management of Zollinger‑Ellison syndrome.” Gastroenterology 2022; 163(3): 855‑867.
7. Strobel, F., et al. “68Ga‑DOTATATE PET/CT for Localization of Gastrinomas.” Journal of Nuclear Medicine 2021; 62(9): 1349‑1356.

```